stoxline Quote Chart Rank Option Currency Glossary
  
Fractyl Health, Inc. (GUTS)
1.08  0.115 (11.87%)    11-18 16:00
Open: 0.995
High: 1.08
Volume: 355,990
  
Pre. Close: 0.9654
Low: 0.9603
Market Cap: 14(M)
Technical analysis
2026-11-18 4:42:33 PM
Short term     
Mid term     
Targets 6-month :  3.39 1-year :  4.91
Resists First :  2.9 Second :  4.21
Pivot price 0.93
Supports First :  0.8 Second :  0.66
MAs MA(5) :  0.95 MA(20) :  0.95
MA(100) :  6.14 MA(250) :  9.93
MACD MACD :  -0.7 Signal :  -0.9
%K %D K(14,3) :  75.8 D(3) :  54.6
RSI RSI(14): 30.9
52-week High :  29.34 Low :  0.8
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ GUTS ] has closed It is unclear right now based on current values. 88.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.08 - 1.09 1.09 - 1.09
Low: 0.95 - 0.95 0.95 - 0.96
Close: 1.07 - 1.08 1.08 - 1.09
Company Description

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Headline News

Thu, 01 Oct 2026
GUTS Shareholder Alert: Fractyl Health, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt - Morningstar

Wed, 30 Sep 2026
FRACTYL HEALTH, INC. (GUTS) SHAREHOLDER ALERT Bernstein - GlobeNewswire

Thu, 24 Sep 2026
GUTS Investor Alert: Fractyl Health, Inc. Securities Class Action Notice - Contact SueWallSt - Morningstar

Wed, 23 Sep 2026
GUTS Deadline Alert: Levi & Korsinsky Reminds Fractyl Health, Inc. (GUTS) Investors of Securities Class Action Deadline on October 20, 2026 - PR Newswire

Fri, 18 Sep 2026
Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Morningstar

Mon, 31 Aug 2026
Deadline Soon: Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 13 (M)
Shares Float 12 (M)
Held by Insiders 1.4 (%)
Held by Institutions 53.2 (%)
Shares Short 265 (K)
Shares Short P.Month 225 (K)
Stock Financials
EPS -10.57
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.13
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -74.6 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -6.4
Qtrly Earnings Growth 0 %
Operating Cash Flow -82 (M)
Levered Free Cash Flow -48 (M)
Stock Valuations
PE Ratio -0.11
PEG Ratio 0
Price to Book value -8.31
Price to Sales 0
Price to Cash Flow -0.18
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

Stoxline iOS

Alpha Bridge iOS

OptionCalc iOS

StockChart Android

Stoxline Android

Alpha Bridge Android

OptionCalc Android